 3. Patient must be receiving an angiotensin converting enzyme ACE inhibitor andor an angiotensin II receptor blocker ARB for at least 3 months prior to screening, where the dose of the ACE inhibitor or the ARB is considered appropriate for that patient, and has been stable and maintained on that dose for at least 8 weeks prior to the Randomization visit 